1. Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
- Author
-
von Delft F, Ronen Gabizon, Wild Cf, Anastassia L. Kantsadi, Peter W. Kenny, Koekemoer L, Matteo P. Ferla, Noam Erez, Sharon Melamed, Adam Smalley, Gijs J. Overheul, Jag Paul Heer, Shaikh A, Tika R. Malla, R.S. Fernandes, Christopher J. Schofield, Moustakas D, Pai R, MacLean B, T. Krojer, Finny S. Varghese, Elad Bar-David, Hagit Achdout, Gregory R. Bowman, Lefker Ba, Kovar B, Charlie Weatherall, Tennant R, Griffen Ej, Yfat Yahalom-Ronen, Louise Dunnett, Emma Cattermole, Bvnbs S, Chernyshenko E, Ripka Eg, Kim Donckers, Efrat Resnick, Nir Paran, J. L. Kiappes, Einat B. Vitner, Dotson Dl, Mark Daniel Calmiano, Juliane Brun, Victor L. Rangel, Matthew F. D. Hurley, Richard Foster, Garrett M. Morris, Vaschetto M, Austin Clyde, Shay Weiss, Pan J, Nir London, William McCorkindale, Dudgeon T, Martin A. Walsh, Borden B, Haim Barr, John Spencer, Zaidmann D, Alice Douangamath, Robinson Rp, Alexandre Dias, John D. Chodera, Morris A, Marian V. Gorichko, Oleg Fedorov, V.O. Gawriljuk, Petra Lukacik, Puni R, Pinjari J, Shafeev M, Dirk Jochmans, Assa Sittner, T.J. Gorrie-Stone, White Km, Amir Ben-Shmuel, Ioannis Vakonakis, Boaz Politi, Rambabu N. Reddi, Joseph E. Coffland, Itai Glinert, Matthew C. Robinson, Ferrins L, Tomasio S, Alpha A. Lee, Khriesto A. Shurrush, Holly Foster, A. Aimon, Boby Ml, Andrea Volkamer, Alessandro Contini, Voelz, Tobias John, Galit Cohen, A.M. Nakamura, Horrell S, G.D. Noske, Jim Bennett, Oleg M. Michurin, Nicholas A. Wright, Smilova, von Delft A, Ward W, Haim Levy, Tomer Israely, Fate G, McGovern Bl, Anna Carbery, David R. Owen, Zidane H, Cox L, Michael Fairhead, Psenak, Carina Gileadi, Wittmann M, Morwitzer Mj, Solmesky Lj, Anthony Tumber, Robert C. Glen, Eric Jnoff, Reid Sp, Sukrit Singh, Steven De Jonghe, Claire Strain-Damerell, Jason C. Cole, A.J. Powell, Rosales R, Nicole Zitzmann, D. Fearon, Nguyen L, Rodriguez-Guerra J, Shirly Duberstein, Andrew Thompson, Johan Neyts, Benjamin Ian Perry, van Rij Rp, Jose Brandao Neto, William G. Glass, Rufa D, Charline Giroud, Peter Eastman, Hannah E. Bruce Macdonald, Glaucius Oliva, Mark A. Hill, Laura Vangeel, Jiye Shi, Hadas Tamir, R. Skyner, Mikolajek H, Adolfo García-Sastre, Oleinikovas, Pingle M, Henry M, Cvitkovic M, Milne Bf, Hart Sh, Eyermann Cj, Thompson W, Matviiuk T, Andre S. Godoy, Swamy, P. Gehrtz, and Jajack A
- Subjects
Open science ,Open knowledge ,Protease ,Structural biology ,Drug discovery ,Computer science ,Non covalent ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,medicine ,Protease inhibitor (pharmacology) ,Computational biology - Abstract
The COVID-19 pandemic was a stark reminder that a barren global antiviral pipeline has grave humanitarian consequences. Pandemics could be prevented in principle by accessible, easily deployable broad-spectrum oral antivirals. Here we report the results of theCOVID Moonshot, a fully open-science, crowd sourced, structure-enabled drug discovery campaign targeting the SARS-CoV-2 main protease. We discovered a novel chemical series that is differentiated from current Mpro inhibitors in that it maintains a new non-covalent, non-peptidic scaffold with nanomolar potency. Our approach leveraged crowdsourcing, high-throughput structural biology, machine learning, and exascale molecular simulations and high-throughput chemistry. In the process, we generated a detailed map of the structural plasticity of the SARS-CoV-2 main protease, extensive structure-activity relationships for multiple chemotypes, and a wealth of biochemical activity data. In a first for a structure-based drug discovery campaign, all compound designs (>18,000 designs), crystallographic data (>840 ligand-bound X-ray structures), assay data (>10,000 measurements), and synthesized molecules (>2,400 compounds) for this campaign were shared rapidly and openly, creating a rich open and IP-free knowledgebase for future anti-coronavirus drug discovery.
- Published
- 2020